Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) reached a new 52-week low on Tuesday after the company announced weaker than expected quarterly earnings. The stock traded as low as $137.00 and last traded at $139.47, with a volume of 283299 shares changing hands. The stock had previously closed at $162.29.
The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on KRYS shares. HC Wainwright restated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital reiterated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday. Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Finally, Guggenheim decreased their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech has a consensus rating of "Buy" and a consensus price target of $218.63.
Read Our Latest Stock Analysis on Krystal Biotech
Insiders Place Their Bets
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.
Hedge Funds Weigh In On Krystal Biotech
Several large investors have recently modified their holdings of KRYS. Entropy Technologies LP bought a new position in shares of Krystal Biotech in the fourth quarter worth $548,000. Janney Montgomery Scott LLC boosted its stake in Krystal Biotech by 42.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock valued at $8,239,000 after buying an additional 15,545 shares during the period. Principal Financial Group Inc. grew its holdings in shares of Krystal Biotech by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock worth $19,340,000 after purchasing an additional 3,727 shares in the last quarter. abrdn plc increased its holdings in shares of Krystal Biotech by 32.5% in the 4th quarter. abrdn plc now owns 57,033 shares of the company's stock worth $8,935,000 after buying an additional 13,979 shares during the last quarter. Finally, Blue Trust Inc. raised its position in Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.
Krystal Biotech Stock Performance
The stock has a 50-day moving average of $171.56 and a two-hundred day moving average of $170.06. The company has a market cap of $3.82 billion, a P/E ratio of 44.22 and a beta of 0.79.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Recommended Stories
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
